Rein Therapeutics, Inc. (RNTX) Operating income 2016–2025
Rein Therapeutics, Inc. (RNTX) annual operating income history from SEC filings — each fiscal year as reported.
-$50.6MFY2025 · since FY2016: -$18.2M → -$50.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$50.6M | +22.2% |
| FY2024 | -$65.1M | -300.0% |
| FY2023 | -$16.3M | +41.1% |
| FY2022 | -$27.6M | -3.9% |
| FY2021 | -$26.6M | -29.8% |
| FY2020 | -$20.5M | +31.6% |
| FY2019 | -$30.0M | +6.1% |
| FY2018 | -$31.9M | -38.7% |
| FY2017 | -$23.0M | -26.6% |
| FY2016 | -$18.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More RNTX financial trends
RNTX RevenueRNTX Net incomeRNTX Net marginRNTX Gross profitRNTX Gross marginRNTX Operating marginRNTX Operating cash flowRNTX Free cash flowRNTX Capital expendituresRNTX Return on equityRNTX Stock buybacksRNTX Dividends paidRNTX Total assetsRNTX Total liabilitiesRNTX Shareholders’ equityRNTX overview →